Belarus vs Morocco: Average cost of multi drug-resistant tuberculosis treatment
Belarus
2,500 constant 2022 US$
in 2023
Morocco
2,000 constant 2022 US$
in 2024
Belarus rank
21st
Morocco rank
22nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Belarus
- Morocco
How they compare
Belarus currently reports 2,500 constant 2022 US$ against 2,000 constant 2022 US$ in Morocco, a difference of 500 constant 2022 US$.
That makes Belarus's figure about 1.2 times Morocco's.
Across all 6 years both countries report, Belarus has been ahead every year.
Belarus ranks 21st and Morocco ranks 22nd of 92 countries.
Belarus has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Belarus | Morocco | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,150 constant 2022 US$ | 2,127 constant 2022 US$ | 3,023 constant 2022 US$ | Belarus |
| 2020s | 4,033 constant 2022 US$ | 1,605 constant 2022 US$ | 2,429 constant 2022 US$ | Belarus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Belarus or Morocco?
- Belarus, at 2,500 constant 2022 US$ against 2,000 constant 2022 US$ in Morocco as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Belarus and Morocco?
- 500 constant 2022 US$, with Belarus ahead.
- How many years of comparable data are there for Belarus and Morocco?
- 6 years are reported by both, from 2017 to 2023.
- How do Belarus and Morocco rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Belarus ranks 21st and Morocco ranks 22nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.